A Recurrent 3'UTR Variant in CAPN3 Highlights the Diagnostic Impact of Non-Coding Variants in Limb-Girdle Muscular Dystrophies.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Estévez-Arias Berta, Segarra-Casas Alba, Seoane Pedro, Romo Lindsay, Polavarapu Kiran, Nectoux Juliette, Caballero-Ávila Marta, Austin-Tse Christina, Konyukh Marina, Obeid Katharina, Hinderhofer Katrin, Aksel-Kilicarslan Ozge, Matalonga Leslie, Rojano Elena, Ranea Juan Ag, O'Heir Emily, Singer-Berk Moriel, O'Leary Melanie, O'Donnell-Luria Anne, Spinazzi Marco, Verebi Camille, Leturcq France, Van Den Bergh Peter, Specht Sabine, de Luna Noemí, de Castro Marta, Roggenbuck Jennifer, Carrera-García Laura, Expósito-Escudero Jesica, Jou Cristina, Ortez Carlos, Llansó Laura, Hernández-Laín Aurelio, Straub Volker, Gallano Pia, Nascimento Andrés, Evangelista Teresinha, Olivé Montse, Domínguez-González Cristina, Lochmüller Hanns, Malfatti Edoardo, Töpf Ana, Gallardo Eduard, González-Quereda Lidia, Natera-de Benito Daniel
Аннотация
METHODS: Clinical assessment, including muscle biopsy and muscle magnetic resonance imaging (MRI), was performed in individuals harboring the CAPN3 c.*534T>C variant. In silico analyses included the assessment of miRNA binding, mRNA secondary structure, creation or disruption of a poly-A tail, and RNA-binding protein (RBP) motifs. A luciferase reporter assay with the c.*534T>C and reference sequence, in the presence or absence of RBFOX1 co-expression, was performed.
RESULTS: We identified 13 individuals from 11 unrelated families presenting with persistent hyperCKemia, commonly accompanied by proximal muscle weakness and myalgia, all harboring the c.*534T>C variant in combination with a previously identified heterozygous CAPN3 variant. Western blot analyses consistently demonstrated absent or markedly reduced calpain-3 expression, and muscle RNA sequencing (RNAseq) showed reduced CAPN3 levels. In silico analyses indicated that the c.*534T>C variant creates a novel binding site for the RNA-binding protein RBFOX1. Luciferase reporter assays supported a regulatory effect of the identified variant on calpain-3 expression.
INTERPRETATION: Our results show that a recurrent non-coding CAPN3 variant causes disease by disrupting post-transcriptional regulation and demonstrate a generalizable principle, as 3'UTR variants can affect mRNA stability and protein expression across neuromuscular and other Mendelian diseases. Although often difficult to interpret as pathogenic, these variants can be therapeutically actionable, highlighting the importance of systematically investigating non-coding regions in unsolved genetic cases. ANN NEUROL 2026.